Journal ArticleOPEN ACCESS

Active Smoking May Negatively Affect Response Rate, Progression-Free Survival, and Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

  • Keizman D
  • Gottfried M
  • Ish-Shalom M
  • et al.
The Oncologist (2014) 19(1) 51-60
DOI: 10.1634/theoncologist.2012-0335
56Citations
Citations of this article
69Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Describe the association between risk factors for renal cell carcinoma and the outcome of sunitinib treatment for metastatic disease. Explain the impact of active smoking on the outcome of sunitinib-treated metastatic renal cell carcinoma. Discuss obesity, hypertension, and diabetes in relation to the outcome of sunitinib-treated metastatic renal cell carcinoma.

Cite

CITATION STYLE

APA

Keizman, D., Gottfried, M., Ish-Shalom, M., Maimon, N., Peer, A., Neumann, A., … Carducci, M. A. (2014). Active Smoking May Negatively Affect Response Rate, Progression-Free Survival, and Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. The Oncologist, 19(1), 51–60. https://doi.org/10.1634/theoncologist.2012-0335

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free